Drug Type Recombinant polypeptide, Biosimilar |
Synonyms teriparatide biosimilar(Accord Healthcare S.L.U.), Sondelbay |
Target |
Action agonists, stimulants |
Mechanism PTH1R agonists(Parathyroid hormone receptor agonists), Osteogenesis stimulants, Parathyroid hormone replacements |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date European Union (24 Mar 2022), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Glucocorticoid-induced osteoporosis | European Union | 24 Mar 2022 | |
Glucocorticoid-induced osteoporosis | Iceland | 24 Mar 2022 | |
Glucocorticoid-induced osteoporosis | Liechtenstein | 24 Mar 2022 | |
Glucocorticoid-induced osteoporosis | Norway | 24 Mar 2022 | |
Osteoporosis, Postmenopausal | European Union | 24 Mar 2022 | |
Osteoporosis, Postmenopausal | Iceland | 24 Mar 2022 | |
Osteoporosis, Postmenopausal | Liechtenstein | 24 Mar 2022 | |
Osteoporosis, Postmenopausal | Norway | 24 Mar 2022 | |
Osteoporotic Fractures | European Union | 24 Mar 2022 | |
Osteoporotic Fractures | Iceland | 24 Mar 2022 | |
Osteoporotic Fractures | Liechtenstein | 24 Mar 2022 | |
Osteoporotic Fractures | Norway | 24 Mar 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoporosis | Phase 3 | India | 26 Oct 2022 |